ESR1 and breast cancer: Previous investigations have indicated that the controlled release of miR-675 from H19 could inhibit estrogen-induced proliferation of ERa+ breast cancer cells.30 Compared with ERa-breast tumors, ERa+ breast tumors exhibited a higher expression of H19.31 In our study, we investigated the association between the H19 polymorphism and estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) for the first time.